LYZZ Capital

LYZZ Capital is a private equity firm based in Shanghai, China, founded in 2015. The firm specializes in venture capital investments at the seed, early, and expansion stages. LYZZ Capital focuses on companies within the healthcare sector, including those involved in medical devices, medical services, and medical digitalization. By targeting innovative businesses in these areas, LYZZ Capital aims to support the development of solutions that enhance healthcare delivery and improve patient outcomes.

Peter Haberz

Principal

Kevin Li

Founding Managing Partner

Katherine Lu

Partner

Tony Ye

Managing Partner

Eric Zhang

Managing Partner

15 past transactions

MojiaBio

Series B in 2022
MojiaBio is a producer of biomanufacturing innovations that aim to improve sustainability. The company, which is dedicated to removing hazardous pollution and excessive energy consumption manufacturing, creates enzyme engineering and biological metabolic pathway engineering platforms to optimize traditional chemical and petroleum production processes.

SUSTAO

Series A in 2022
SUSTAO is a manufacturer of consumables that meet the technical requirements of medical robots.

OncoMyx Therapeutics

Series B in 2021
OncoMyx Therapeutics, Inc., established in 2018 and based in Phoenix, Arizona, specializes in the development of oncolytic immunotherapies. The company's core focus is the myxoma virus (MYXV), a unique oncolytic virus that targets both hematologic and solid tumors. OncoMyx's innovative approach involves a patented systemic delivery method, enabling the virus to be carried by human leukocytes to tumor cells, thereby stimulating an immune response to fight cancer.

OncoMyx Therapeutics

Series B in 2021
OncoMyx Therapeutics, Inc., established in 2018 and based in Phoenix, Arizona, specializes in the development of oncolytic immunotherapies. The company's core focus is the myxoma virus (MYXV), a unique oncolytic virus that targets both hematologic and solid tumors. OncoMyx's innovative approach involves a patented systemic delivery method, enabling the virus to be carried by human leukocytes to tumor cells, thereby stimulating an immune response to fight cancer.

Wugen

Series B in 2021
Wugen is focused on developing off-the-shelf cellular therapies for cancer, particularly utilizing natural killer (NK) cells and CAR-T cell therapies. The company enhances NK cells obtained from healthy donors to improve their ability to target and eliminate cancer cells. Wugen's innovative approach includes a proprietary platform that leverages advanced genomic engineering to create next-generation memory NK cell therapies. These therapies specifically aim to address various types of malignancies, including solid tumors, acute myeloid leukemia, and T-cell malignancies, thereby providing new treatment options for patients facing life-threatening cancers.

Neurelis

Series D in 2021
Neurelis is a specialty pharmaceutical company based in Encinitas, California, focused on addressing unmet medical needs in epilepsy and the broader central nervous system market. Established in 2007, the company develops and commercializes product candidates utilizing innovative technologies to improve therapeutic benefits and patient care. Neurelis leverages its expertise in neuroscience to enhance drug delivery mechanisms, enabling the effective administration of a wide range of therapeutic agents, including proteins, peptides, and both large and small molecules. Through its differentiated approach, Neurelis aims to provide solutions that significantly improve treatment outcomes for patients suffering from epilepsy and related conditions.

Jumpcode Genomics

Funding Round in 2020
Jumpcode Genomics, founded by Keith Brown in 2016 and based in Carlsbad, California, specializes in genome technology aimed at enhancing sequencing workflows. The company has developed CRISPR-mediated rRNA depletion kits, utilizing its proprietary CRISPRclean technology to selectively remove unwanted nucleic acid molecules from sequencing libraries. This innovative approach aims to improve detection sensitivity and performance while maintaining the integrity of non-targeted sequences. By integrating seamlessly with standard library preparation services, Jumpcode Genomics' solutions help researchers reduce bias, lower costs, and simplify their workflows, thereby enabling more effective applications of genomic information to address various global challenges.

Onchilles Pharma

Venture Round in 2020
Onchilles Pharma is a biotechnology company based in San Diego, California, founded in 2017. The company focuses on developing first-in-class biologic therapies specifically targeting cancer cells while sparing normal cells and tissues, which enhances treatment efficacy for cancer patients. By leveraging novel neutrophil and macrophage biology, Onchilles Pharma aims to create innovative myeloid-focused cancer therapeutics and advance the next generation of immunotherapies. Through its research and development efforts, the company seeks to provide medical professionals with effective tools to combat cancer.

Mabworks

Series C in 2020
Beijing Mabworks Biotech, a gene engineering mAb company. Mabworks is working on ZMapp, an Ebola treatment developed by San Diego's MAPP Biopharma. It also is developing two clinical stage drug candidates: MIL60, a biosimilar to Genentech's Avastin, and MIL62, a proposed treatment for chronic lymphocytic leukemia.

Qpex Biopharma

Series A in 2018
Qpex Biopharma is a San Diego-based biopharmaceutical company founded in 2018, focused on developing innovative therapies to address the growing challenge of antimicrobial resistance. The company specializes in creating a pipeline of antibiotic drugs aimed at treating infectious diseases in both inpatient and outpatient settings. With a strong emphasis on the discovery, development, and regulatory approval of anti-infective medicines, Qpex Biopharma leverages its expertise and experience in collaboration with public and private partnerships to meet critical medical needs. The company's mission is to provide effective solutions for healthcare professionals facing the complexities of resistant infections, thereby enhancing treatment options for patients.

Alpha Biopharma

Series A in 2018
Alpha Biopharma Inc. is a biopharmaceutical company based in Huangpu, China, focused on researching and developing innovative therapeutics. The company is primarily engaged in the clinical development of AZD3759, a small molecule tyrosine kinase inhibitor aimed at treating patients with epidermal growth factor receptor (EGFR) mutation positive non-small cell lung cancer (NSCLC) who have central nervous system (CNS) metastases. To enhance its research and development capabilities, Alpha Biopharma collaborates with prominent international pharmaceutical companies and utilizes a strong scientific consultancy and management team. The company emphasizes a comprehensive strategy that includes research and development, market engagement, and intellectual property protection. Additionally, it partners with leading contract research organizations (CROs), contract manufacturing organizations (CMOs), hospitals, and institutes to ensure the effective implementation of its programs through meticulous project management.

NewMed Medical

Series A in 2018
NewMed Medical Co., Ltd. is a Shanghai-based company focused on the research, development, manufacture, and marketing of interventional artificial heart valve systems. Established in 2015, the company specializes in producing artificial heart valves and transcather implantation systems designed to replace diseased mitral valves. These innovative products aim to simplify heart valve replacement surgery, thereby reducing treatment risks and facilitating quicker patient recovery while also lowering surgical costs. Through its advancements in medical technology, NewMed Medical contributes to improved outcomes in cardiac care.

Neurelis

Series B in 2017
Neurelis is a specialty pharmaceutical company based in Encinitas, California, focused on addressing unmet medical needs in epilepsy and the broader central nervous system market. Established in 2007, the company develops and commercializes product candidates utilizing innovative technologies to improve therapeutic benefits and patient care. Neurelis leverages its expertise in neuroscience to enhance drug delivery mechanisms, enabling the effective administration of a wide range of therapeutic agents, including proteins, peptides, and both large and small molecules. Through its differentiated approach, Neurelis aims to provide solutions that significantly improve treatment outcomes for patients suffering from epilepsy and related conditions.

Neurelis

Series A in 2016
Neurelis is a specialty pharmaceutical company based in Encinitas, California, focused on addressing unmet medical needs in epilepsy and the broader central nervous system market. Established in 2007, the company develops and commercializes product candidates utilizing innovative technologies to improve therapeutic benefits and patient care. Neurelis leverages its expertise in neuroscience to enhance drug delivery mechanisms, enabling the effective administration of a wide range of therapeutic agents, including proteins, peptides, and both large and small molecules. Through its differentiated approach, Neurelis aims to provide solutions that significantly improve treatment outcomes for patients suffering from epilepsy and related conditions.

Chipscreen

Venture Round in 2015
Chipscreen is an integrated biotech company focused on the discovery and development of novel small molecule pharmaceuticals. Established in 2001 as a Sino-foreign joint venture, the company was founded by a group of esteemed Chinese returnees with academic and industrial expertise. Chipscreen employs a proprietary chemical genomics-based discovery platform to create a diverse portfolio of clinical and preclinical programs across various therapeutic areas. The company emphasizes a science-driven approach, strong pipeline development, and expertise in intellectual property and regulatory matters. Its business strategy involves either developing drug candidates independently or in partnership with other organizations throughout the research, preclinical, and clinical stages.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.